GlassScriptPhysician profile
Randall Carlton
NPI 1295791523
$12,754.59
in general payments reported to CMS, 2019-2025
56 companies · $2,233 in 2025
The $2,233 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,947 · 2020: $1,525 · 2021: $1,825 · 2022: $1,713 · 2023: $2,015 · 2024: $1,497 · 2025: $2,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,745.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,675.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,472.84 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $1,443.63 | 2019-2025 | |
| Novo Nordisk INC | $1,216.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $902.28 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $611.76 | 2019-2025 | Repatha, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $549.06 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $458.63 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $420.08 | 2019-2023 | Gardasil 9 |
| Allergan, INC. | $358.46 | 2019-2020 | |
| Astellas Pharma US INC | $331.16 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $312.54 | 2021-2025 | |
| Glaxosmithkline, LLC. | $296.24 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $256.65 | 2023-2025 | Rexulti |
| Medtronic, INC. | $235.27 | 2024-2025 | Intellis Adaptivestim, Osteocool Rf Ablation System |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Carlton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.